Views

View May 18, 2026

Can Most-Favored Nation (MFN) Pricing Deliver on Cost Savings Promise?

View May 18, 2026

Specialty Pharmaceuticals Face Access Challenges in the AI Era

View May 13, 2026

Patients as Partners US 2026: Expert Insights

View May 11, 2026

Harmonizing Case Validation for Vaccine Safety in Real-World Data: The VAC4EU Experience

View May 11, 2026

Understanding the Unmet Needs of People with MS at Diagnosis and Throughout Their Care Journey: Insights from a Survey-Based Study

View May 6, 2026

From Data to Decisions: What EMA’s RW-DQF Means for Regulatory Use of Real-World Data

View May 4, 2026

FDA Cosmetics Oversight Update for MoCRA Implementation

View May 1, 2026

The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing

View May 1, 2026

Making the Jump from “Coverage assumed” to “Access proven”: The New Equity Imperative in Market Access

View Apr 30, 2026

Digital Narrative Intelligence (DNI): Seeing the Full Story Across Social, Search, and Generative AI

View Apr 22, 2026

Shaping the Future of Health Empowerment

View Apr 21, 2026

Cancer Progress 2026

View Apr 15, 2026

Expert Insights From the MAPS Americas 2026 Meeting

View Apr 7, 2026

Keeping Hope Alive: How Pre-POC Oncology Biotech Can Successfully Navigate Current Challenging Times

House of cards made of standard playing cards with the text "AI" replacing numbers

View Apr 7, 2026

AI in Life Sciences Without Governance Is a House of Cards

View Apr 6, 2026

Foundayo’s 50‑Day FDA Approval

1 2 3 4 5 6 … 24